Heiligenstein J H, Faries D E, Rush A J, Andersen J S, Pande A C, Roffwarg H P, Dunner D, Gillin J C, James S P, Lahmeyer H
Psychopharmacology Division, Lilly Research Laboratories, Indianapolis, IN 46285.
Psychiatry Res. 1994 Jun;52(3):327-39. doi: 10.1016/0165-1781(94)90078-7.
Fluoxetine and placebo were compared in 89 outpatients with major depression with (n = 45) or without (n = 44) a reduced or shortened rapid eye movement latency (SREML) (< or = 65 minutes) to determine whether rapid eye movement latency (REML) predicted placebo and/or antidepressant response. Men and women were stratified based on polysomnographic recordings and then randomly assigned to receive double-blind fluoxetine (20 mg/day) or placebo for 8 weeks after a 2-week, single-blind, placebo lead-in period. Fluoxetine-treated patients demonstrated a significantly greater reduction in the Hamilton Rating Scale for Depression total score and a significantly greater response rate than placebo-treated patients in both the SREML and the combined strata. Treatment differences in the non-SREML stratum were not statistically significant. Results supported REML as a predictor of placebo nonresponse but did not predict a differential fluoxetine response in patients with SREML compared with patients without SREML.
对89名重度抑郁症门诊患者进行了比较，这些患者有（n = 45）或没有（n = 44）快速眼动睡眠潜伏期缩短或缩短（SREML）（≤65分钟），以确定快速眼动睡眠潜伏期（REML）是否能预测安慰剂和/或抗抑郁药的反应。根据多导睡眠图记录对男性和女性进行分层，然后在为期2周的单盲安慰剂导入期后，随机分配接受双盲氟西汀（20毫克/天）或安慰剂治疗8周。在SREML和合并分层中，氟西汀治疗的患者在汉密尔顿抑郁量表总分上的降低幅度显著大于安慰剂治疗的患者，反应率也显著更高。非SREML分层中的治疗差异无统计学意义。结果支持REML作为安慰剂无反应的预测指标，但未预测出与无SREML的患者相比，有SREML的患者对氟西汀的反应有差异。
